| 0000-00-00 |
|
|
|
External link to document |
| 2022-10-27 |
12 |
Patent/Trademark Report to Commissioner of Patents |
;7,176,211 B2 ;7,419,983 B2 ;10,537,572 B2 ;10,682,351 B2 ;11,344,551 B2. (vfm) (Entered: 10/28/2022)… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,056,927 B2 ;… 27 October 2022
1:22-cv-01423
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
| 2023-12-01 |
163 |
Notice of Service |
Solco Healthcare US, LLC for U.S. Patent Nos. 11,542,239, 10,537,572, and 10,682,351; (4) Plaintiffs' …Contentions Against Alkem Laboratories Limited for U.S. Patent No. 11,542,239; (2) Plaintiffs' Initial Infringement…Labs Limited Unit-V, and Hetero USA Inc. for U.S. Patent No. 11,542,239; (3) Plaintiffs' Initial Infringement… Sun Pharmaceutical Industries Limited for U.S. Patent No. 11,542,239; and (5) Plaintiffs' Initial Infringement…Biophore India Pharmaceuticals Private Ltd. for U.S. Patent No. 11,542,239 filed by AbbVie Inc., AbbVie Ltd |
External link to document |
| 2024-03-07 |
196 |
Claim Construction Chart |
phrases in U.S. Patent Nos. 7,419,983 (“the ’983 patent”),
10,537,572 (“the ’572 patent”), 10,682,351 …10,682,351 (“the ’351 patent”), and 11,542,239 (“the ’239
patent”).1, 2
The parties agree that no terms…the ’239 patent require construction.
With respect to the ’572, ’351, and ’983 patents, the parties…351 Patent, Claim 1 elagolix sodium”
’572 Patent, Claims… ’572 patent, claim 1, 2
’351 patent, claim 1
|
External link to document |
